Cancer

Subterms

    More stories

    • 125 Shares99 Views

      in Energy

      Institute Professor Paula Hammond named to White House science council

      by

      Paula Hammond, an MIT Institute Professor and head of MIT’s Department of Chemical Engineering, has been chosen to serve on the President’s Council of Advisors on Science and Technology (PCAST), the White House announced today.

      The council advises the president on matters involving science, technology, education, and innovation policy. It also provides the White House with scientific and technical information that is needed to inform public policy relating to the U.S. economy, U.S. workers, and national security.

      “For me, this is an exciting opportunity,” Hammond says. “I have always been interested in considering how science can solve important problems in our community, in our country, and globally. It’s very meaningful for me to have a chance to have an advisory role at that level.”

      Hammond is one of 30 members named to the council, which is co-chaired by Frances Arnold, a professor at Caltech, and Maria Zuber, MIT’s vice president for research.

      “Paula is an extraordinary engineer, teacher, and colleague, and President Biden’s decision to appoint her to the council is an excellent one,” Zuber says. “I think about the work ahead of us — not just to restore science and technology to their proper place in policymaking, but also to make sure that they lead to real improvements in the lives of everyone in our country — and I can’t think of anyone better suited to the challenge than Paula.”

      Hammond, whose research as a chemical engineer touches on the fields of both medicine and energy, said she hopes to help address critical issues such as equal access to health care and efforts to mitigate climate change.

      “I’m very excited about the opportunities presented at the interface of engineering and health, and in particular, how we might be able to expand the benefits that we gain from our work to a broader set of communities, so that we’re able to address some of the disparities we see in health, which have been so obvious during the pandemic,” says Hammond, who is also a member of MIT’s Koch Institute for Integrative Cancer Research. “How we might be able to use everything from computational modeling and data science to technological innovation to equalize access to health is one area that I care a lot about.”

      Hammond’s research focuses on developing novel polymers and nanomaterials for a variety of applications in drug delivery, noninvasive imaging, solar cells, and battery technology. Using techniques for building polymers with highly controlled architectures, she has designed drug-delivering nanoparticles that can home in on tumors, as well as polymer films that dramatically improve the efficiency of methanol fuel cells.

      As an MIT faculty member and mentor to graduate students, Hammond has worked to increase opportunities for underrepresented minorities in science and engineering fields. That is a goal she also hopes to pursue in her new role.

      “There’s a lot of work to be done when we look at the low numbers of students of color who are actually going on to science and engineering fields,” she says. “When I think about my work related to increasing diversity in those areas, part of the reason I do it is because that’s where we gain excellence, and where we gain solutions and the foresight to work on the right problems. I also think that it’s important for there to be broad access to the power that science brings.”

      Hammond, who earned both her bachelor’s degree and PhD from MIT, has been a member of the faculty since 1995. She has been a full professor since 2006 and has chaired the Department of Chemical Engineering since 2015. Earlier this year, she was named an Institute Professor, MIT’s highest faculty honor. She is also one of only 25 people who have been elected to all three National Academies — Engineering, Science, and Medicine.

      She has previously served on the U.S. Secretary of Energy Scientific Advisory Board, the NIH Center for Scientific Review Advisory Council, and the Board of Directors of the American Institute of Chemical Engineers. She also chaired or co-chaired two committees that contributed landmark reports on gender and race at MIT: the Initiative for Faculty Race and Diversity, and the Academic and Organizational Relationships Working Group. More

    • 150 Shares159 Views

      in Environment

      Study: Global cancer risk from burning organic matter comes from unregulated chemicals

      by

      Whenever organic matter is burned, such as in a wildfire, a power plant, a car’s exhaust, or in daily cooking, the combustion releases polycyclic aromatic hydrocarbons (PAHs) — a class of pollutants that is known to cause lung cancer.

      There are more than 100 known types of PAH compounds emitted daily into the atmosphere. Regulators, however, have historically relied on measurements of a single compound, benzo(a)pyrene, to gauge a community’s risk of developing cancer from PAH exposure. Now MIT scientists have found that benzo(a)pyrene may be a poor indicator of this type of cancer risk.

      In a modeling study appearing today in the journal GeoHealth, the team reports that benzo(a)pyrene plays a small part — about 11 percent — in the global risk of developing PAH-associated cancer. Instead, 89 percent of that cancer risk comes from other PAH compounds, many of which are not directly regulated.

      Interestingly, about 17 percent of PAH-associated cancer risk comes from “degradation products” — chemicals that are formed when emitted PAHs react in the atmosphere. Many of these degradation products can in fact be more toxic than the emitted PAH from which they formed.

      The team hopes the results will encourage scientists and regulators to look beyond benzo(a)pyrene, to consider a broader class of PAHs when assessing a community’s cancer risk.

      “Most of the regulatory science and standards for PAHs are based on benzo(a)pyrene levels. But that is a big blind spot that could lead you down a very wrong path in terms of assessing whether cancer risk is improving or not, and whether it’s relatively worse in one place than another,” says study author Noelle Selin, a professor in MIT’s Institute for Data, Systems and Society, and the Department of Earth, Atmospheric and Planetary Sciences.

      Selin’s MIT co-authors include Jesse Kroll, Amy Hrdina, Ishwar Kohale, Forest White, and Bevin Engelward, and Jamie Kelly (who is now at University College London). Peter Ivatt and Mathew Evans at the University of York are also co-authors.

      Chemical pixels

      Benzo(a)pyrene has historically been the poster chemical for PAH exposure. The compound’s indicator status is largely based on early toxicology studies. But recent research suggests the chemical may not be the PAH representative that regulators have long relied upon.   

      “There has been a bit of evidence suggesting benzo(a)pyrene may not be very important, but this was from just a few field studies,” says Kelly, a former postdoc in Selin’s group and the study’s lead author.

      Kelly and his colleagues instead took a systematic approach to evaluate benzo(a)pyrene’s suitability as a PAH indicator. The team began by using GEOS-Chem, a global, three-dimensional chemical transport model that breaks the world into individual grid boxes and simulates within each box the reactions and concentrations of chemicals in the atmosphere.

      They extended this model to include chemical descriptions of how various PAH compounds, including benzo(a)pyrene, would react in the atmosphere. The team then plugged in recent data from emissions inventories and meteorological observations, and ran the model forward to simulate the concentrations of various PAH chemicals around the world over time.

      Risky reactions

      In their simulations, the researchers started with 16 relatively well-studied PAH chemicals, including benzo(a)pyrene, and traced the concentrations of these chemicals, plus the concentration of their degradation products over two generations, or chemical transformations. In total, the team evaluated 48 PAH species.

      They then compared these concentrations with actual concentrations of the same chemicals, recorded by monitoring stations around the world. This comparison was close enough to show that the model’s concentration predictions were realistic.

      Then within each model’s grid box, the researchers related the concentration of each PAH chemical to its associated cancer risk; to do this, they had to develop a new method based on previous studies in the literature to avoid double-counting risk from the different chemicals. Finally, they overlaid population density maps to predict the number of cancer cases globally, based on the concentration and toxicity of a specific PAH chemical in each location.

      Dividing the cancer cases by population produced the cancer risk associated with that chemical. In this way, the team calculated the cancer risk for each of the 48 compounds, then determined each chemical’s individual contribution to the total risk.

      This analysis revealed that benzo(a)pyrene had a surprisingly small contribution, of about 11 percent, to the overall risk of developing cancer from PAH exposure globally. Eighty-nine percent of cancer risk came from other chemicals. And 17 percent of this risk arose from degradation products.

      “We see places where you can find concentrations of benzo(a)pyrene are lower, but the risk is higher because of these degradation products,” Selin says. “These products can be orders of magnitude more toxic, so the fact that they’re at tiny concentrations doesn’t mean you can write them off.”

      When the researchers compared calculated PAH-associated cancer risks around the world, they found significant differences depending on whether that risk calculation was based solely on concentrations of benzo(a)pyrene or on a region’s broader mix of PAH compounds.

      “If you use the old method, you would find the lifetime cancer risk is 3.5 times higher in Hong Kong versus southern India, but taking into account the differences in PAH mixtures, you get a difference of 12 times,” Kelly says. “So, there’s a big difference in the relative cancer risk between the two places. And we think it’s important to expand the group of compounds that regulators are thinking about, beyond just a single chemical.”

      The team’s study “provides an excellent contribution to better understanding these ubiquitous pollutants,” says Elisabeth Galarneau, an air quality expert and PhD research scientist in Canada’s Department of the Environment. “It will be interesting to see how these results compare to work being done elsewhere … to pin down which (compounds) need to be tracked and considered for the protection of human and environmental health.”

      This research was conducted in MIT’s Superfund Research Center and is supported in part by the National Institute of Environmental Health Sciences Superfund Basic Research Program, and the National Institutes of Health. More